AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 10.61 |
Market Cap | 7.97B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 5.54 |
PE Ratio (ttm) | 1.98 |
Forward PE | n/a |
Analyst | Buy |
Ask | 11.49 |
Volume | 4,675,366 |
Avg. Volume (20D) | 4,694,301 |
Open | 10.82 |
Previous Close | 10.74 |
Day's Range | 10.81 - 11.25 |
52-Week Range | 9.69 - 13.05 |
Beta | undefined |
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aur...
Analyst Forecast
According to 8 analyst ratings, the average rating for ROIV stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 64.31% from the latest price.
Next Earnings Release
Analysts project revenue of $5.00M, reflecting a -86.54% YoY shrinking and earnings per share of -0.22, making a 4.76% increase YoY.
2 months ago · seekingalpha.com
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring VolatilityRoivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and Dermavant ha...